Telix Pharmaceuticals
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WATelix Pharmaceuticals Limited (TLX) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation.
TLX is headquartered in Melbourne with international operations in Brussels, Kyoto and Indianapolis. It is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.
Telix Pharmaceuticals won AusBiotech's Company Of The Year award in 2022.
Contact Details
Suite 401, 55 Flemington Road, NORTH MELBOURNE VIC 3051
0449 148 448
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Telix Pharmaceuticals | $499.1m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 127th | Telix Pharmaceuticals | 78% | 77% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEW ROLE: D Smith, | 02 Mar 2023 |
| NEW ROLE: R Valeix, | 02 Mar 2023 |
| NEW ROLE: C Hayward, | 02 Mar 2023 |
| NEWS: Tagged in AusBiotech honours WA research pair, Forrests | 27 Oct 2022 |
| NEW ROLE: G Liberatore, Group Chief Operating Officer | 24 Nov 2020 |
| NEW ROLE: D Cubbin, Chief Financial Officer | 24 Nov 2020 |
| NEW ROLE: Harry McCann, Non-Executive Chair | 03 Nov 2020 |
| NEW ROLE: Jann Skinner, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Christian Behrenbruch, Chief Executive, Managing Director | 03 Nov 2020 |
